Wermke M, Gambardella V, Kuboki Y, Felip E, et al. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. J Clin Oncol 2025 Jul 24:JCO2500363. doi: 10.1200/JCO-25-00363.
PMID: 40706016